- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04668339
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants
This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults.
The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19:
As 2 doses (at two different dose levels), separated by 28 days or as 1 dose
In adults 18 years of age and older
Study Overview
Status
Conditions
Detailed Description
This is a multiregional, multicenter, Phase 2, randomized, observer-blind study designed to evaluate the safety, reactogenicity, and immunogenicity of the study vaccine in younger and older adult participants. Enrolled participants will be randomly assigned to receive either study vaccine ARCT-021 or placebo (sterile saline).
Approximately 600 participants (300 each in younger [18 to <56 years of age in United States or 21 to <56 years of age in Singapore] and older [≥56 years of age] participants) will be enrolled (including at least 50% of participants in the older cohort ≥65 years of age). Participants will be stratified by age and then randomly assigned (3 ARCT-021:1 placebo) to receive 2 doses of study vaccine separated by 28 days. At 180 days after second study vaccination (Day 208), participants in Study Groups 1, 2, and 3 will be randomly assigned again to receive a single booster dose of study vaccine (randomly assigned as 1 ARCT-021:1 placebo). Study Group 4 will not be randomized but will receive 1 dose of placebo at Day 208. Study Groups are summarized in Table 1. Study vaccine will be administered in an observer-blind fashion. Participants will be followed for safety and immunogenicity through 180 days after booster vaccination (Day 388). At a subset of clinical sites, all enrolled participants will also undergo blood sampling for evaluation of CMI responses.
Vaccine doses will be assigned as follows:
Younger Age Cohort:
Study Group 1: n= 75 participants, ARCT-021 7.5 µg (first dose), Placebo (second dose Study Group 2: n= 75 participants, ARCT-021 5.0 µg (first dose), 5.0 µg (second dose) Study Group 3: n= 75 participants, ARCT-021 7.5 µg (first dose), 7.5 µg (second dose) Study Group 4: n= 75 participants, Placebo (first dose), Placebo (second dose)
Booster Vaccine:
Study Groups 1, 2, 3: 113 participants, ARCT-021 5.0 µg or 7.5 µg, 112 participants, Placebo Study Group 4: n= 75 participants, Placebo
Older Age Cohort:
Study Group 1: n= 75 participants, ARCT-021 7.5 µg (first dose), Placebo (second dose Study Group 2: n= 75 participants, ARCT-021 5.0 µg (first dose), 5.0 µg (second dose) Study Group 3: n= 75 participants, ARCT-021 7.5 µg (first dose), 7.5 µg (second dose) Study Group 4: n= 75 participants, Placebo (first dose), Placebo (second dose)
Booster Vaccine:
Study Groups 1, 2, 3: 113 participants, ARCT-021 5.0 µg or 7.5 µg, 112 participants, Placebo Study Group 4: n= 75 participants, Placebo
A DSMB will be in place to independently review the safety data of participants. Pausing Rules are also utilized in this study to reduce risk to study participants.
The expected duration of participation for an individual participant is approximately 14 months, inclusive of the Screening period.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 117599
- Arcturus Investigational Site 204
-
Singapore, Singapore, 169608
- Arcturus Investigational Site 201
-
Singapore, Singapore, 308433
- Arcturus Investigational Site 203
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Arcturus Investigational Site 103
-
Tucson, Arizona, United States, 85741
- Arcturus Investigational Site 107
-
-
California
-
San Diego, California, United States, 92108
- Arcturus Investigational Site 112
-
-
Florida
-
Melbourne, Florida, United States, 32934
- Arcturus Investigational Site 104
-
Orlando, Florida, United States, 32806
- Arcturus Investigational Site 105
-
Pinellas Park, Florida, United States, 33781
- Arcturus Investigational Site 106
-
The Villages, Florida, United States, 32162
- Arcturus Investigational Site 109
-
-
Illinois
-
Peoria, Illinois, United States, 61614
- Arcturus Investigational Site 101
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Arcturus Investigational Site 110
-
-
South Carolina
-
Anderson, South Carolina, United States, 29621
- Arcturus Investigational Site 102
-
-
Texas
-
Austin, Texas, United States, 78705
- Arcturus Investigational Site 111
-
Dallas, Texas, United States, 75234
- Arcturus Investigational Site 108
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Individuals who:
- are able to provide consent
- agree to comply with all study visits and procedures
- are willing and able to adhere to study restrictions
- are sexually active and willing to adhere to contraceptive requirements
- are male or female ≥18 or (in Singapore) ≥21 years of age
- are medically stable
Exclusion Criteria:
Individuals who:
- have had SARS-CoV-2 infection or COVID-19 disease.
- have had cancer except for cancers that were treated and that have low risk of returning
- have chronic kidney disease
- have some chronic lung diseases
- have some heart conditions
- have compromised immune systems
- are obese
- have sickle cell disease or some other blood disorders
- are current smokers and/or use illegal drugs
- have Type 2 diabetics
- are immunocompromised, immunodeficient or have had a transplant
- have autoimmune disease
- have other severe or uncontrolled diseases or disease that may interfere with the interpretation of the study
- have a positive test for hepatitis B or C or human immunodeficiency virus
- have had a severe reaction to previous investigational vaccines
- have a fever or are feeling sick close to the time of the first vaccination of the study
- have positive drug test at screening
- are pregnant
- are breastfeeding
- have a bleeding disorder
- have previously received an investigational coronavirus vaccine (SARS-CoV(1) or MERS) or who plan to be in other COVID-19 studies
- have recently been vaccinated with other vaccines
- have recently received blood products
- who work at one of the clinic sites participating in this study, work at Arcturus, who work at other companies that monitor the study or close family members to the sites, Arcturus, or partners involved in study monitoring
- other restrictions may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study Group 1, Younger Adult Participants
Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
|
ARCT-021 higher dose (one dose) + placebo (one dose)
ARCT-021 (single dose) OR placebo, booster
|
Experimental: Study Group 2, Younger Adult Participants
Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
|
ARCT-021 (single dose) OR placebo, booster
ARCT-021 lower dose (two doses, Day 0 and Day 28)
|
Experimental: Study Group 3, Younger Adult Participants
Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
|
ARCT-021 (single dose) OR placebo, booster
ARCT-021 higher dose (two doses, Day 0 and Day 28)
|
Placebo Comparator: Study Group 4, Younger Adult Participants
Participants will receive one of Placebo (Saline) on Day 0, one dose of Placebo on Day 28, and one dose of Placebo on Day 208
|
Placebo (two doses, Day 0 and Day 28)
Placebo (single dose)
|
Experimental: Study Group 1, Older Adult Participants
Participants will receive one dose of ARCT-021 on Day 0, one dose of Placebo (saline) on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
|
ARCT-021 higher dose (one dose) + placebo (one dose)
ARCT-021 (single dose) OR placebo, booster
|
Experimental: Study Group 2, Older Adult Participants
Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
|
ARCT-021 (single dose) OR placebo, booster
ARCT-021 lower dose (two doses, Day 0 and Day 28)
|
Experimental: Study Group 3, Older Adult Participants
Participants will receive one dose of ARCT-021 on Day 0, a second dose of ARCT-021 on Day 28 and on Day 208 either one dose of ARCT-021 or one dose of placebo
|
ARCT-021 (single dose) OR placebo, booster
ARCT-021 higher dose (two doses, Day 0 and Day 28)
|
Placebo Comparator: Study Group 4, Older Adult Participants
Participants will receive one dose of Placebo (saline) on Day 0, a second dose of Placebo on Day 28 and a third dose of Placebo on Day 208
|
Placebo (two doses, Day 0 and Day 28)
Placebo (single dose)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentages of participants reporting solicited local adverse events
Time Frame: for 7 days following each dose administration
|
Adverse events reported daily in a diary that reflect common symptoms or findings at the injection site following vaccination
|
for 7 days following each dose administration
|
Percentages of participants reporting solicited systemic adverse events
Time Frame: for 7 days following each dose administration
|
Adverse events reported daily in a diary that reflect generalized symptoms following vaccination
|
for 7 days following each dose administration
|
Percentages of participants reporting adverse events
Time Frame: 28 days following each dose administration
|
spontaneously reported adverse events
|
28 days following each dose administration
|
Percentages of participants reporting serious adverse events
Time Frame: Day 0 to Day 388
|
unsolicited adverse events that meet the definition of serious
|
Day 0 to Day 388
|
Percentages of participants reporting medically attended adverse events
Time Frame: Day 0 to Day 388
|
unsolicited adverse events that lead to healthcare provider visit
|
Day 0 to Day 388
|
Percentages of participants reporting new onset of chronic disease
Time Frame: Day 0 to Day 388
|
unsolicited adverse events associated with new diagnosis of chronic disease
|
Day 0 to Day 388
|
Percentages of participants with abnormal chemistry and hematology values
Time Frame: Day 0 to Day 215
|
chemistry and hematology
|
Day 0 to Day 215
|
SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs
Time Frame: Day 0 to Day 388
|
neutralizing antibody response
|
Day 0 to Day 388
|
Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs
Time Frame: Through Day 388
|
neutralizing antibody response
|
Through Day 388
|
Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels
Time Frame: Through Day 388
|
neutralizing antibody response
|
Through Day 388
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels, expressed as GMCs
Time Frame: Day 0 to Day 388
|
SARS-CoV-2 anti S1, RBD, N binding antibody responses
|
Day 0 to Day 388
|
Changes in SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs
Time Frame: Through Day 388
|
SARS-CoV-2 anti S1, RBD, N binding antibody responses
|
Through Day 388
|
Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels
Time Frame: Through Day 388
|
SARS-CoV-2 anti S1, RBD, N binding antibody responses
|
Through Day 388
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Severe Acute Respiratory Syndrome
- COVID-19
- Coronavirus Infections
- Infections
- Communicable Diseases
Other Study ID Numbers
- ARCT-021-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on ARCT-021 single dose priming
-
Arcturus Therapeutics, Inc.Completed
-
Arcturus Therapeutics, Inc.Terminated
-
Arcturus Therapeutics, Inc.RecruitingCOVID-19 | Corona Virus Infection | SARS-CoV-2 InfectionUnited States, Singapore
-
Genentech, Inc.CompletedUlcerative ColitisBelgium, Spain, New Zealand, United States, Czech Republic, Germany, Australia, United Kingdom, Israel, Hungary, Canada
-
Pharming Technologies B.V.CompletedGenetic DisordersNetherlands
-
AblynxCompletedHealthy VolunteersUnited States
-
Taiho Pharmaceutical Co., Ltd.CompletedStress Urinary IncontinenceJapan
-
PfizerCompleted
-
Galapagos NVCompleted
-
Bridge Biotherapeutics, Inc.KCRN Research, LLCCompletedHealthy ParticipantsUnited States